[ad_1]
SAN DIEGO, March 1, 2024 (GLOBE NEWSWIRE) — Fate Therapeutics, Inc. (the “Company” or “Fate Therapeutics”) (NASDAQ: FATE) is a clinical-stage biopharmaceutical company committed to bringing best-in-class Products, a pipeline of induced pluripotent stem cell (iPSC)-derived cellular immunotherapies for patients with cancer and autoimmune diseases, today announced that the company will participate in the following upcoming investor meetings:
TD Cowan 44th Annual Healthcare Conference, Wednesday, March 6th2024, 9:10 a.m. ET, Boston, Massachusetts
Leerink Global Biopharmaceutical Conference, Monday, March 11th2024, 2:00 PM ET, Miami, Florida
Barclays 26th Annual Global Healthcare Conference, Tuesday, March 12th2024 at 11:15 a.m. ET in Miami, Florida
Jefferies Biotech Gulf Summit will be held on Wednesday, March 13thin Miami, FL in 2024
The 2nd Annual HC Wainwright Cell Therapy Virtual Conference will be held on Tuesday, March 26th2024 at 3:00 pm (ET)
A live webcast of each presentation (if recorded) may be accessed under “Events and Presentations” in the Investor section of the Company’s website at www.fatetherapeutics.com. An archived webcast will be available on the company’s website shortly after the event.
About Fate Therapeutics, Inc.
Fate Therapeutics is a clinical-stage biopharmaceutical company focused on delivering first-in-class induced pluripotent stem cell (iPSC)-derived cellular immunotherapies to patients with cancer and autoimmune diseases. Leveraging its proprietary iPSC product platform, the company has established leadership in the creation of multi-engineered master iPSC lines as well as the manufacturing and clinical development of off-the-shelf iPSC-derived cell products. The company’s pipeline includes iPSC-derived natural killer (NK) cell and T cell product candidates that are selectively engineered to incorporate novel synthetic control of cell function and are designed to provide patients with multiple therapeutic mechanisms. Fate Therapeutics is headquartered in San Diego, California. For more information, please visit www.fatetherapeutics.com.
touch:
Christina Tartaglia
Stern Investor Relations
212.362.1200
christina.tartaglia@sternir.com
[ad_2]
Source link